Oncology & Cancer

Expression, genomic patterns predict sarcoma progression

(HealthDay)—The Complexity Index in Sarcoma (CINSARC) and Genomic Index prognostic signatures are valid independent methods of assessing synovial sarcoma (SS) prognosis, according to a study published online Jan. 14 in ...

Oncology & Cancer

New drug overcomes resistance in patients with rare sarcoma

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report ...

Oncology & Cancer

Regorafenib active in metastatic GI stromal tumors

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according ...

Medications

Novartis says EU approves expanded use of Glivec

Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

Oncology & Cancer

Three 'targeted' cancer drugs raise risk of fatal side effects

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...

page 4 from 4